Jia Ming
9 Papers
1 Citations
Jia Ming is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 6 publications.
Chat about Author
Papers
Human type III collagen-derived biomaterial with high antitumor activity inhibits breast cancer cell autophagy, proliferation, and migration through DDR1.
TL;DR: In this article , the authors found that recombinant humanized collagen type III (rhCOLIII) not only promoted apoptosis and dormancy of BCCs but also inhibited autophagy within BCCs.
7
Risk of waning humoral responses after inactivated or subunit recombinant SARS‐CoV‐2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China
Hui Li,Dachuan Cai,Depeng Jiang,Xingsheng Li,Xiao-Bo Liao,Dongfang Liu,Zuojin Liu,Peng Zhu,Guo-Bing Yin,Jia Ming,Mingli Peng,Min Chen,Ning Ling,Yinghua Lan,Da-Zhi Zhang,Peng Hu,Hong Ren +16 more
TL;DR: In this paper , the authors investigated the impact of the presence of comorbidities on the humoral response to SARS-CoV-2 vaccination in patients with chronic disease (PWCD) and assessed the effect of the number of coexisting diseases on the immune response to vaccination.
6
Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study
TL;DR: In this paper , the role of ER and PR balance in breast cancer progression and individualized treatment was investigated in two large groups and three subgroups, including the ER+/PR+/HER2-patients.
Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors
Zhiwei Chen,Peng Zhu,Zuojin Liu,Bin-lin Zhu,Guo-Bing Yin,Jia Ming,Rui Song,Qi Pan,Tong Li,Xin Jiang,Bin Wang,Shuaibin Liu,Hongxing Cai,Jingjie Wang,Yu-Ling Han,Zijing Lin,Yang Hong,Min Chen,Mingli Peng,Li Hu,Dachuan Cai,Hong Ren +21 more
TL;DR: Wang et al. as mentioned in this paper performed a prospective observational study to evaluate receptor-binding domain IgG antibody (antiRBD-IgG), neutralizing antibodies (NAbs) and memory B cells (MBCs) responses, and monitor adverse events (AEs) in patients with solid tumors and healthy controls from 21-105 days after full-course of inactivated SARSCoV-2 vaccines.
4
Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
Shanshan Han,Yuping Yang,Ting Wang,Rui Song,Daixing Hu,Mingli Peng,Zi-Jing Lin,Qin Deng,Hong Ren,Jia Ming +9 more
TL;DR: In this article , the authors evaluated the safety and immunogenicity of the third (booster) dose of the COVID-19 vaccine for patients with endocrine-related cancers.